Introduction: Lenalidomide is an active agent that was approved for use in the EU in 2015 as a
the total costs associated with newly diagnosed multiple myeloma over 5 years in the EU5 based on treatment duration and time to progression (TTP) (taken from trial data). We compared a baseline scenario (of current lenalidomide uptake) with two alternative future scenarios. Conclusions: Compared to other first line therapies, lenalidomide delays time to
INTRODUCTION
Multiple myeloma is an incurable haematologic cancer, accounting for 1% of all cancers and approximately 10% of all haematologic malignancies [1] . The treatment paradigm of induction followed by maintenance to progression has now been clearly demonstrated to increase progression-free survival (PFS) and overall survival (OS). However, myeloma management is complicated because nearly all patients relapse and become refractory [2] . Clinicians must consider several factors when making treatment decisions: patient preference and access to treatment, age, comorbidities and frailty [3] .
Lenalidomide is an efficacious multiple myeloma treatment previously licensed for use in relapsed and refractory disease. It was licensed in the EU as a first-line therapy in 2015, and in light of data from the FIRST study [3, 4] 
METHODS

Lenalidomide Efficacy
To demonstrate the average time to progression of an entire multiple myeloma care pathway, treatment sequences that included lenalidomide-based therapy in first line were compared with treatment sequences that included thalidomide-or bortezomib-based regimens as first-line options.
Lenalidomide First-Line Uptake in the EU5
We developed a cost-impact model to estimate the total costs associated with newly diagnosed multiple myeloma over 5 years in the EU5. We We sourced hospitalisation costs from a retrospective chart review of Dutch patients with relapsed/refractory multiple myeloma [10] . We adapted these costs to the first-line setting by adjusting for the duration of treatment (DoT) and the time to progression (TTP) as reported in the clinical trials of each regimen (shown in Table 1 ). It is worth noting that DoT data may also include treatment-free intervals associated with some treatments. The model has been designed using TTP data; time to next treatment data were not available within the trials because of the variability in starting a new treatment line.
Drug costs were calculated according to drug prices and dosing (i.e., the number of doses per month multiplied by the total mg per dose multiplied by the cost per mg). Weighted averages were used to calculate listed drug prices across the EU5. Monthly costs within the line of treatment were equated to the sum of hospital-based costs (visits, admission, procedures, concomitant medication) as published by Gaultney et al. [10] . Hospital costs in the first-line treatment setting were not described by Gaultney et al.; therefore, hospital costs in the second-line treatment setting were adjusted to TTP and applied to first-line use, assuming the same monthly cost during treatment time.
We compared a baseline scenario (of current lenalidomide uptake) with two alternative future scenarios. The baseline scenario reflected the estimated current uptake of first-line lenalidomide (i.e., 11% of the market). For Future Scenario A, we assumed a steadily increasing uptake of first-line lenalidomide: up to 50% in Year 5. The baseline 11% market share for lenalidomide was taken from bortezomib-based and thalidomide-based regimens so that,
proportionally, the relative market share of these two comparators remained the same. Table 2 shows the baseline scenario and assumed market share of therapies at first line. Table 3 shows the market share overrides after first-line therapies for Future Scenario A.
Scenario Estimating Potential Impact of Triple Therapy
Future Scenario B was identical to baseline scenario, but we also assumed a 20% increased uptake of carfilzomib-based triple therapy (KRd) at second-line. Furthermore, a small percentage of patients in both future scenarios were assumed to receive a re-treatment. For example, VMP after first-line [19] . Table 2 shows the baseline scenario and assumed market share of therapies at first-line and Table 3 shows the market share overrides for Future Scenario A. Table 4 shows the market share overrides after first-line therapies for Future Scenario B. BORT bortezomib, LEN lenalidomide, THAL thalidomide a Pomalidomide-based regimens assumed to be used exclusively after third line; some patients were assumed to receive a re-treatment, e.g., MPT after first-line MPT Monthly costs within the line of treatment were the sum of hospital based costs published by Gaultney et al. [10] .
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In Future Scenario B, we modelled a 20% uptake of the novel triplet combination KRd at second line; we estimated that the impact on the budget will represent an additional 29% increase over the current baseline scenario. In contrast, modelling a future care pathway with increasing first-line lenalidomide resulted in a budget impact of only 8% over the current baseline, as shown in Fig. 3 .
DISCUSSION
Our results show that the availability of lenalidomide at first-line has a relatively small impact on budget, i.e., an 8% increase. This increase should be considered both within the context of the increased benefit expected for patients in terms of TTP and OS, and when compared to the potential impact of introducing triple combination therapy with a novel agent as first-line salvage for the 20% of patients we estimated to be fit enough to receive this treatment later in their treatment pathway (29% increase in budget impact). Not all patients are eligible for triple therapy during subsequent lines of treatment; this is especially relevant in the context of an increasingly elderly population. Although there are no direct, randomised data comparing Rd and VMP, lenalidomide is expected to be more (€109,000) lower than for first-line bortezomib [8] . These findings further support our recommendation that the most beneficial way 
